Vasculitis Overview - Concepedia

Principles

Definition

Vasculitis is a medical concept and research area focused on the study of inflammatory diseases affecting blood vessels. This field investigates the diverse etiologies, pathogenetic mechanisms, classification, diagnosis, and clinical manifestations of these conditions, which are significant due to their potential to cause tissue damage and organ dysfunction.

Ontological type

Pathogenesis

Diagnostic Evaluation

Therapeutic Strategies

Key developments

Key Figures

Immune-Complex Era era

Anthony S. Fauci [1] emerged as a leading figure in the Immune-Complex Era (1947–1981), with affiliations including Harvard University [2] and the University of Washington [3] during this period. His work culminated in the 1978 paper The Spectrum of Vasculitis [4], which articulated the spectrum of vasculitis and underscored immune-complex–driven injury across vessel sizes, shaping nosology and prognosis-driven management for the era. Fauci [1] helped translate these immunopathologic insights into clinical frameworks that emphasized prognosis and therapeutic rationales based on immune-complex pathology in vasculitis during this era. Through his synthesis of histopathology and clinical correlation, Fauci [1] contributed to a more cohesive understanding of vasculitis as an immune-complex–mediated process, influencing research and practice in this era.

ANCA and Mechanisms era

Wolfgang L. Gross[1], affiliated with Heidelberg University[3] and Johannes Gutenberg University Mainz[4], helped shape the biomarker-driven vasculitis paradigm in this era. In this era his key contributions include Netting neutrophils in autoimmune small-vessel vasculitis[7], which highlighted neutrophil extracellular traps as a mechanistic bridge between serologic markers and endothelial injury, underscoring the relevance of mechanistic endpoints. J. T. Lie[2], affiliated with Harvard University[5] and Northwestern University[6], helped advance standardized classification schemes during this era. His key contribution was The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa[8], which provided standardized diagnostic criteria and enabled phenotype-driven cohorts and trial inclusion, aligning nosology with biomarker-driven approaches.

Targeted Therapy Era era

Peter A. Merkel [1] is a leading vasculitis researcher associated with Harvard University [3] and Johns Hopkins University [4] during the Targeted Therapy Era. Merkel [1] helped establish the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides [6], a standard that enabled cross-study comparability and underpinned mechanism-based, targeted therapy advances in this era. David Jayne [2], with ties to Harvard University [3] and University of California, San Francisco [5], contributed to the 2012 nomenclature paper [6], providing a unified vocabulary that clarified disease entities for translational work in targeted therapies. This standardization supported the era's emphasis on mechanism-based regimens, imaging and biomarker-guided risk stratification, and multi-center trial infrastructure enabling steroid-sparing, targeted approaches in vasculitis.